Look for Drugs and Conditions

Representative image

Akums Drugs & Pharmaceuticals Ltd. Marks 20th Anniversary with "BHAROSA" Campaign

Akums Drugs & Pharmaceuticals Limited, a leading contract development and manufacturing organization (CDMO) in India, has launched its 20th Anniversary Campaign, "BHAROSA – Two Decades of Trust, Going Strong." This campaign commemorates a significant milestone in Akums' journey within the pharmaceutical manufacturing industry, underscoring its unwavering commitment to sustainability and innovation.

The Indian pharmaceutical market witnessed remarkable growth in 2023, reaching a value of US$ 22.7 billion. Projections indicate a continued upward trajectory, with expectations for the market to expand to US$ 35.09 billion by 2028, reflecting a compound annual growth rate (CAGR) of 9.5% during the period of 2023-2028.

Akums has been at the forefront of this growth, demonstrating market leadership and a dedication to innovation. In FY23, Akums commanded a market share of 9.3% of the total addressable Indian domestic CDMO market by value and 8.8% in the IPM market by volume. Notably, its market share in the Indian domestic CDMO market surged to 29.4% by value in FY23, up from 26.7% in FY21.

Mr. Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., expressed his appreciation on this significant occasion, stating, "April 19, 2004, marks a significant milestone for Akums as we celebrate two decades of longstanding and trusted relationships. Our dedication lies in continuously inspiring and fortifying this trust while cultivating collaborative relationships with all our stakeholders. We work diligently to adapt to customer demands and strive to develop innovative formulations, contributing to the communities in which we operate."

Echoing Mr. Jain's sentiments, Mr. Sandeep Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., emphasized the company's vision for the future, "Since its inception in 2004, Akums has established its commitment to innovation and excellence, manufacturing over 4,000 commercialized formulations across more than 60 dosage forms and therapeutic areas.

With a focus on research and development, we have developed over 200 formulations to address the evolving needs of our clientele. Our long-term vision for 2030 is to emerge as a global leader in pharmaceutical contract development and manufacturing, while upholding our values of trust, excellence, and innovation."

Recognized as the 'Dream Employer of the Year' in 2023 by Times Ascent, Akums prioritizes workforce development to ensure product safety and consistency. With a global presence spanning 53 countries, the company holds major certifications such as WHO-GMP, ISO 9001:2015, and ISO 14001:2015, along with various international accreditations. Akums has received numerous awards and accolades, including the India Pharma Award for Excellence in Contract Research & Manufacturing for 2021 by Informa Markets.

As Akums embarks on its journey of continued growth and innovation, the "BHAROSA" Campaign serves as a testament to its position as a trusted and long-term resource within the pharmaceutical industry.

Be first to post your comments

Post your comment

Related Articles

Ad 5